advertisement
Abstract #18365 Published in IGR 3-3
Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist
Hellberg MR; Sallee VL; McLaughlin MA; Sharif NA; DeSantis L; Dean TR; Zinke PWJournal of Ocular Pharmacology and Therapeutics 2001; 17: 421-432
Travoprost is the isopropyl ester prodrug of a high affinity, selective FP prostaglandin full receptor agonist. In contrast to travoprost acid's high affinity and efficacy at the FP receptor, there is only sub-micromolar affinity for the DP, EP1 EP3, EP4, IP, and TP receptors. Travoprost produced a lower incidence of ocular irritation than PGF2α> isopropyl ester at a dose of 1 μg in the New Zealand albino (NZA) rabbit. Topical ocular application of travoprost produced a marked miotic effect in cats following doses of 0.01, 0.03, and 0.1 μg. In the ocular hypertensive monkey, b.i.d. application of 0.1 and 0.3 μg of travoprost afforded peak reduction in intraocular pressure (IOP) of 22.7 and 28.6%, respectively. Topical application of travoprost was well tolerated in rabbits, cats and monkeys, causing no ocular irritation or discomfort at doses of up to 1 μg. Travoprost is a promising ocular hypotensive prostaglandin FP derivative that has the ocular hypotensive efficacy of PGF2α> isopropyl ester but with less severe ocular side-effects.
Dr M.R. Hellberg, Alcon Research Ltd, 6201 South Freeway, Fort Worth, TX 76134, USA. Mark.Hellberg@AlconLabs.com
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)